(Q35835203)

English

A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer

scientific article published on 14 February 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 August 2017

A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer (English)

1 reference

Europe PubMed Central

10 August 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

A A Chiappori

1

1 reference

Europe PubMed Central

10 August 2017

M T Schreeder

2

1 reference

Europe PubMed Central

10 August 2017

M M Moezi

3

1 reference

Europe PubMed Central

10 August 2017

J J Stephenson

4

1 reference

Europe PubMed Central

10 August 2017

J Blakely

5

1 reference

Europe PubMed Central

10 August 2017

R Salgia

6

1 reference

Europe PubMed Central

10 August 2017

Q S Chu

7

1 reference

Europe PubMed Central

10 August 2017

H J Ross

8

1 reference

Europe PubMed Central

10 August 2017

D S Subramaniam

9

1 reference

Europe PubMed Central

10 August 2017

J Schnyder

10

1 reference

Europe PubMed Central

10 August 2017

M S Berger

11

1 reference

Europe PubMed Central

10 August 2017

language of work or name

0 references

publication date

14 February 2012

1 reference

Europe PubMed Central

10 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

10 August 2017

106

1 reference

Europe PubMed Central

10 August 2017

839-845

1 reference

Europe PubMed Central

10 August 2017

5

1 reference

Europe PubMed Central

10 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.2012.21

0 references

Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

The landscape of somatic copy-number alteration across human cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

Unique biology of Mcl-1: therapeutic opportunities in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

Bcl-xL inhibitor ABT-737 reveals a dual role for Bcl-xL in synaptic transmission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

Prophylactic cranial irradiation in extensive small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

Management of small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

Multidisciplinary management of lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

Small cell carcinomas of the lung express the Bcl-2 protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

11 July 2018

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.21

21 January 2018

A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.21

21 January 2018

Bcl-2 family proteins are essential for platelet survival.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3305978

24 September 2018

Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/22333598

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2012.21

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35835203&oldid=1966786518"